Azithramycine

Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.

Cross Reference

Introduction

To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Azithramycine?

Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Azithramycine

MeSH term MeSH ID Detail
Reproductive Tract Infections D060737 1 associated lipids
Chlamydial Pneumonia D061387 2 associated lipids
Pneumonia, Lipid D011017 2 associated lipids
Protozoan Infections D011528 6 associated lipids
Tick Bites D064927 1 associated lipids
Granulomatous Mastitis D058890 1 associated lipids
Per page 10 20 50 100 | Total 276

PubChem Associated disorders and diseases

What pathways are associated with Azithramycine

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Azithramycine?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Azithramycine?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Azithramycine?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Azithramycine?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Azithramycine?

Mouse Model

Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).

Knock-out

Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).

Tissue Model

Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Azithramycine

Download all related citations
Per page 10 20 50 100 | Total 4404
Authors Title Published Journal PubMed Link
Roblin PM et al. In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae. 2003 Antimicrob. Agents Chemother. pmid:12604555
Schiedler V et al. Pattern of antibiotic use in a trachoma-endemic region of Nepal: implications for mass azithromycin distribution. 2003 Ophthalmic Epidemiol pmid:12607157
Mesa FL et al. Antibiotic treatment of incipient drug-induced gingival overgrowth in adult renal transplant patients. 2003 J. Periodont. Res. pmid:12608908
[Uncomplicated community-acquired pneumonia. Under control in 3 treatment days]. 2003 MMW Fortschr Med pmid:12619240
Song Z and Wang C Ultrasensitive assay of azithromycin in medicine and bio-fluids based on its enhanced luminol-H(2)O(2) chemiluminescence reaction using flow injection technique. 2003 Bioorg. Med. Chem. pmid:14642581
Mecaskey JW et al. The possibility of eliminating blinding trachoma. 2003 Lancet Infect Dis pmid:14592604
Arreaza L et al. Emergence of gonococcal strains with resistance to azithromycin in Spain. 2003 J. Antimicrob. Chemother. pmid:12493814
Lobzin IuV et al. [New achievements in the diagnosis and treatment of disseminated urogenital chlamydiosis]. 2003 Vestn. Akad. Med. Nauk SSSR pmid:14598508
Adachi JA et al. Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico. 2003 Clin. Infect. Dis. pmid:14557959
Schriever C et al. Red wine, resveratrol, Chlamydia pneumoniae and the French connection. 2003 Atherosclerosis pmid:14644410
Jennings MB et al. Comparison of azithromycin and cefadroxil for the treatment of uncomplicated skin and skin structure infections. 2003 Cutis pmid:14533837
Callaghan R and Allen M Mycobacterium malmoense infection of the knee. 2003 Ann. Rheum. Dis. pmid:14583565
Feldman RB et al. Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: a 31/2-year experience from a veterans affairs hospital. 2003 Arch. Intern. Med. pmid:12885688
Dunne MW et al. Randomized, double-blind study of the clinical efficacy of 3 days of azithromycin compared with co-amoxiclav for the treatment of acute otitis media. 2003 J. Antimicrob. Chemother. pmid:12888586
Rush C and Simon MW The effect of amoxicillin-clavulanate, cefixime and azithromycin on normal throat flora in children with group A streptococcal pharyngitis. 2003 Clin Pediatr (Phila) pmid:12862350
Lildholdt T et al. The natural history of recurrent acute tonsillitis and a clinical trial of azithromycin for antibiotic prophylaxis. 2003 Clin Otolaryngol Allied Sci pmid:12871256
Crum NF et al. Halting a pneumococcal pneumonia outbreak among United States Marine Corps trainees. 2003 Am J Prev Med pmid:12880877
Bhattacharya MK et al. Azithromycin in the treatment of cholera in children. 2003 Acta Paediatr. pmid:12856976
Farley TA et al. The acceptability and behavioral effects of antibiotic prophylaxis for syphilis prevention. 2003 Sex Transm Dis pmid:14603093
Favre-Bonté S et al. Biofilm formation by Pseudomonas aeruginosa: role of the C4-HSL cell-to-cell signal and inhibition by azithromycin. 2003 J. Antimicrob. Chemother. pmid:12951348
Taylor WR et al. Tolerability of azithromycin as malaria prophylaxis in adults in northeast papua, indonesia. 2003 Antimicrob. Agents Chemother. pmid:12821468
Seral C et al. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. 2003 Antimicrob. Agents Chemother. pmid:12821480
Katusic D et al. Azithromycin vs doxycycline in the treatment of inclusion conjunctivitis. 2003 Am. J. Ophthalmol. pmid:12654359
Carryn S et al. Activity of beta-lactams (ampicillin, meropenem), gentamicin, azithromycin and moxifloxacin against intracellular Listeria monocytogenes in a 24 h THP-1 human macrophage model. 2003 J. Antimicrob. Chemother. pmid:12654747
Danesi R et al. Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg. 2003 J. Antimicrob. Chemother. pmid:12654753
Zhanel GG et al. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations. 2003 J. Antimicrob. Chemother. pmid:12775677
Blandford JM and Gift TL The cost-effectiveness of single-dose azithromycin for treatment of incubating syphilis. 2003 Sex Transm Dis pmid:12782951
Castaldo RS et al. A comparison of 5-day courses of dirithromycin and azithromycin in the treatment of acute exacerbations of chronic obstructive pulmonary disease. 2003 Clin Ther pmid:12749513
Putnam SD et al. Antimicrobial susceptibility trends in Campylobacter jejuni and Campylobacter coli isolated from a rural Egyptian pediatric population with diarrhea. 2003 Diagn. Microbiol. Infect. Dis. pmid:14711482
Guchev IA et al. [Effect of chemoprophylaxis on pneumonia incidence in organized groups]. 2003 Voen Med Zh pmid:12722514
Maekawa M et al. [Alteration of antibacterial activity of tosufloxacin and various antibacterial agents against Streptococcus pneumoniae]. 2003 Jpn J Antibiot pmid:12723396
Johnson SR et al. Mutations causing in vitro resistance to azithromycin in Neisseria gonorrhoeae. 2003 Int. J. Antimicrob. Agents pmid:12727073
Skerk V et al. Comparative analysis of azithromycin and ciprofloxacin in the treatment of chronic prostatitis caused by Chlamydia trachomatis. 2003 Int. J. Antimicrob. Agents pmid:12727080
Trad O et al. Eradication of Cryptosporidium in four children with acute lymphoblastic leukemia. 2003 J. Trop. Pediatr. pmid:12729299
Zhou WQ et al. [Clinic efficacy of treating chronic prostatitis caused by Neisseria gonorrhoeae with azithromycin aspartic-acid injection]. 2003 Zhonghua Nan Ke Xue pmid:12680331
Ioannidis J and Wilkinson D HIV: prevention of opportunistic infections. 2003 Clin Evid pmid:15555123
Schilling F [Chronic recurrent multifocal osteomyelitis. Opinion exchange concerning the article by T. Seidl et al in Der Orthopäde (2003) 32:535-540]. 2003 Orthopade pmid:14655012
Lin L et al. A retrospective study on clinical features of and treatment methods for 77 severe cases of SARS. 2003 Am. J. Chin. Med. pmid:14992536
Aznabaev MT et al. [Use of cycloferon in a combined treatment of chlamydial conjunctivitis]. 2003 Jan-Feb Vestn Oftalmol pmid:12608044
Scheinfeld NS et al. Macrolides in dermatology. 2003 Jan-Feb Clin. Dermatol. pmid:12609587
Bevan CD et al. Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. 2003 Jan-Feb J. Int. Med. Res. pmid:12635534
Prata A et al. Efficacy of azithromycin in the treatment of cutaneous leishmaniasis. 2003 Jan-Feb Rev. Soc. Bras. Med. Trop. pmid:12715065
Knuf M et al. [Lymphadenitis colli due to non-tuberculous mycobacteria (NTM): a case-series and review of the literature]. 2003 Jan-Feb Klin Padiatr pmid:12545419
Bernstein JM The farmer and the tractor. 2003 Mar-Apr Skinmed pmid:14673307
Aktan B et al. Effect of macrolide antibiotics on nitric oxide synthase and xanthine oxidase activities, and malondialdehyde level in erythrocyte of the guinea pigs with experimental otitis media with effusion. 2003 Nov-Dec Pol J Pharmacol pmid:14730107
Khandekarf R and Mohammed AJ Outcome of azithromycin treatment of active trachoma in Omani school children. 2003 Sep-Nov East. Mediterr. Health J. pmid:16450533
Frenck RW et al. Short-course azithromycin for the treatment of uncomplicated typhoid fever in children and adolescents. 2004 Clin. Infect. Dis. pmid:15034826
Smelov V et al. Azithromycin treatment follow-up: antibacterial susceptibility of Chlamydia trachomatis in patients with chronic prostatitis. 2004 Int. J. Antimicrob. Agents pmid:15037332
Manavi K et al. The prevalence of rectal chlamydial infection amongst men who have sex with men attending the genitourinary medicine clinic in Edinburgh. 2004 Int J STD AIDS pmid:15038860
Hartmann M [Therapy of syphilis]. 2004 Hautarzt pmid:14968333
Law C and Amsden GW Single-dose azithromycin for respiratory tract infections. 2004 Ann Pharmacother pmid:14970367
Kanazawa S et al. Azithromycin and bronchiolitis obliterans. 2004 Am. J. Respir. Crit. Care Med. pmid:14982826
Imamura Y et al. Azithromycin inhibits MUC5AC production induced by the Pseudomonas aeruginosa autoinducer N-(3-Oxododecanoyl) homoserine lactone in NCI-H292 Cells. 2004 Antimicrob. Agents Chemother. pmid:15328111
Ngan CC et al. Susceptibility testing of Singapore strains of Mycoplasma hominis to tetracycline, gatifloxacin, moxifloxacin, ciprofloxacin, clindamycin, and azithromycin by the Etest method. 2004 Diagn. Microbiol. Infect. Dis. pmid:15023431
Máiz Carro L and Cantón Moreno R [Azithromycin therapy in cystic fibrosis]. 2004 Med Clin (Barc) pmid:15030744
Baumann U et al. Long term azithromycin therapy in cystic fibrosis patients: a study on drug levels and sputum properties. 2004 Can. Respir. J. pmid:15045047
Cafini F et al. Bactericidal activity of moxifloxacin against multidrug-resistant Streptoccocus pneumoniae at clinically achievable serum and epithelial lining fluid concentrations compared with three other antimicrobials. 2004 Int. J. Antimicrob. Agents pmid:15380257
Erdeve O et al. The probiotic effect of Saccharomyces boulardii in a pediatric age group. 2004 J. Trop. Pediatr. pmid:15357564
Tsai WC et al. Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. 2004 Am. J. Respir. Crit. Care Med. pmid:15361366
Skerk V et al. Azithromycin: 4.5- or 6.0-gram dose in the treatment of patients with chronic prostatitis caused by Chlamydia trachomatis--a randomized study. 2004 J Chemother pmid:15332719
AltintaÅŸ E et al. Comparison of ranitidine bismuth citrate, tetracycline and metronidazole with ranitidine bismuth citrate and azithromycin for the eradication of Helicobacter pylori in patients resistant to PPI based triple therapy. 2004 Turk J Gastroenterol pmid:15334317
Berquand A et al. Real-time imaging of drug-membrane interactions by atomic force microscopy. 2004 Biochim. Biophys. Acta pmid:15328052
Mariotti SP New steps toward eliminating blinding trachoma. 2004 N. Engl. J. Med. pmid:15525727
Southern KW and Barker PM Azithromycin for cystic fibrosis. 2004 Eur. Respir. J. pmid:15516680
Smelov V et al. In vitro activity of fluoroquinolones, azithromycin and doxycycline against chlamydia trachomatis cultured from men with chronic lower urinary tract symptoms. 2004 Eur. Urol. pmid:15474277
Nariai A et al. [Efficacy of azithromycin as the empiric therapy in children with community-acquired pneumonia who were isolated macrolide resistant Streptococcus pneumoniae from nasopharynx]. 2004 Kansenshogaku Zasshi pmid:15287476
Atasoy M et al. Treatment of confluent and reticulated papillomatosis with azithromycin. 2004 J. Dermatol. pmid:15492444
Lukehart SA et al. Macrolide resistance in Treponema pallidum in the United States and Ireland. 2004 N. Engl. J. Med. pmid:15247355
Chidambaram JD et al. Mass antibiotic treatment and community protection in trachoma control programs. 2004 Clin. Infect. Dis. pmid:15494901
Sugie M et al. Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin. 2004 Antimicrob. Agents Chemother. pmid:14982769
Antibiotics ineffective for prevention of recurrent MI. 2004 J Fam Pract pmid:15251088
Kim YS et al. A comparative trial of a single dose of azithromycin versus doxycycline for the treatment of mild scrub typhus. 2004 Clin. Infect. Dis. pmid:15494910
Mizunoe S et al. Clarithromycin and azithromycin induce apoptosis of activated lymphocytes via down-regulation of Bcl-xL. 2004 Int. Immunopharmacol. pmid:15251115
Panpanich R et al. Azithromycin for acute lower respiratory tract infections. 2004 Cochrane Database Syst Rev pmid:15497172
Bouwman JJ et al. Azithromycin inhibits interleukin-6 but not fibrinogen production in hepatocytes infected with cytomegalovirus and chlamydia pneumoniae. 2004 J. Lab. Clin. Med. pmid:15252403
Koytchev R et al. Assessment of the bioequivalence of different formulations containing azithromycin (tablets and suspension). 2004 Arzneimittelforschung pmid:15497663
Tindberg Y et al. Helicobacter pylori eradication in children and adolescents by a once daily 6-day treatment with or without a proton pump inhibitor in a double-blind randomized trial. 2004 Aliment. Pharmacol. Ther. pmid:15274666
Halpern MT and Cifaldi MA Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia? 2004 Clin. Infect. Dis. pmid:15206068
Carr RR and Nahata MC Azithromycin for improving pulmonary function in cystic fibrosis. 2004 Ann Pharmacother pmid:15213312
Romanowska-Sarlej J et al. Ultrastructure of the hepatocytes after application of azithromycin (Sumamed). 2004 Ann Univ Mariae Curie Sklodowska Med pmid:16146049
Gonzalez BE et al. Azithromycin compared with beta-lactam antibiotic treatment failures in pneumococcal infections of children. 2004 Pediatr. Infect. Dis. J. pmid:15131461
Shibata Y et al. [Evaluation of anti-inflammatory effect of macrolides on macrophages]. 2004 Jpn J Antibiot pmid:16108591
Parry CM The treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever in Viet Nam. 2004 Trans. R. Soc. Trop. Med. Hyg. pmid:15138078
Mizunoe T et al. [The mechanism of apoptosis induction in lymphocytes by macrolide antibiotics and the related intra-cellular molecular structure]. 2004 Jpn J Antibiot pmid:16108600
Paik JW et al. Inhibition of cyclosporin A-induced gingival overgrowth by azithromycin through phagocytosis: an in vivo and in vitro study. 2004 J. Periodontol. pmid:15088875
Guchev IA et al. Two regimens of azithromycin prophylaxis against community-acquired respiratory and skin/soft-tissue infections among military trainees. 2004 Clin. Infect. Dis. pmid:15095213
Miron D et al. Azithromycin as an alternative to nalidixic acid in the therapy of childhood shigellosis. 2004 Pediatr. Infect. Dis. J. pmid:15071299
Palcevski G et al. Antibiotic use profile at paediatric clinics in two transitional countries. 2004 Pharmacoepidemiol Drug Saf pmid:15072118
Gross M et al. Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor. 2004 J. Antimicrob. Chemother. pmid:14963065
Kyebambe P Incomplete Reiter's arthritis in a 23 year old nursing mother. 2004 Afr Health Sci pmid:15687073
Matic V et al. Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin. 2004 Antimicrob. Agents Chemother. pmid:15504828
Kosowska K et al. Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae. 2004 Antimicrob. Agents Chemother. pmid:15504829
Fernandez-Obregon A Oral use of azithromycin for the treatment of acne rosacea. 2004 Arch Dermatol pmid:15096385
Fernandez AD et al. Azithromycin modulates murine immune responses to pneumococcal conjugate vaccine and inhibits nasal clearance of bacteria. 2004 J. Infect. Dis. pmid:15499531
Pokrovskaia EV [Final confirmation of inefficiency of antibiotics in secondary prevention of coronary heart disease. Results of PROVE IT (gatifloxacin trial) and ACES]. 2004 Kardiologiia pmid:15477798
Brandén E et al. Intermittent azithromycin treatment for respiratory symptoms in patients with chronic Chlamydia pneumoniae infection. 2004 Scand. J. Infect. Dis. pmid:15764166
Carter G et al. A subinhibitory concentration of clarithromycin inhibits Mycobacterium avium biofilm formation. 2004 Antimicrob. Agents Chemother. pmid:15561879
Soni N et al. Recurrent acute interstitial nephritis induced by azithromycin. 2004 Pediatr. Infect. Dis. J. pmid:15602202
Zervos M et al. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia. 2004 Treat Respir Med pmid:15606222
Jones S et al. The tip of the iceberg: opportunistic screening for Chlamydia trachomatis in asymptomatic patients attending a young people's health clinic reveals a high prevalence--a pilot study. 2004 Sex Health pmid:16334993